Transient expansion of peptide‐specific lymphocytes producing IFN‐γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage‐A1/A3‐positive tumors

Assessment of T‐cell activation is pivotal for evaluation of cancerimmunotherapy. We initiated a clinical trial in patients with MAGE‐A1and/or ‐A3 tumors using autologous DC pulsed with MAGE peptides aimedat analyzing T‐cell‐derived, IFN‐γ secretion by cytokine flowcytometry and ELISPOT. We also tested whether further KLH additioncould influence this response favorably. Monocyte‐derived DC weregenerated from leukapheresis products. They were pulsed with therelevant MAGE peptide(s) alone in group A (n=10 pts) andadditionally with KLH in group B (n=16 pts). A specific buttransient increase in the number of peripheral blood T lymphocytessecreting IFN‐γ in response to the vaccine peptide(s) was observed in6/8 patients of group A and in 6/16 patients of group B. We concludethat anti‐tumor vaccination using DC pulsed with MAGE peptides inducesa potent but transient anti‐MAGE, IFN‐γ secretion that is notinfluenced by the additional delivery of a nonspecific, T‐cellhelp.

[1]  N. Restifo,et al.  Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen , 2000, The Journal of Immunology.

[2]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[3]  J. Shabanowitz,et al.  Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[4]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[5]  Matteo Bellone,et al.  Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.

[6]  M. Moser,et al.  Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. , 1999, Journal of immunology.

[7]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[8]  W. Mehal,et al.  TCR ligation on CD8+ T cells creates double-negative cells in vivo. , 1998, Journal of immunology.

[9]  P. Coulie,et al.  Estimation of the frequencies of anti‐MAGE‐3 cytolytic T‐lymphocyte precursors in blood from individuals without cancer , 1998, International journal of cancer.

[10]  A. McMichael,et al.  A New Look at T Cells , 1998, The Journal of experimental medicine.

[11]  R. Offringa,et al.  Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. , 1998, Journal of immunology.

[12]  H. Klocker,et al.  Differential deactivation of human dendritic cells by endotoxin desensitization: role of tumor necrosis factor-alpha and prostaglandin E2. , 1998, Blood.

[13]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[14]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[15]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[16]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[17]  P. Romero,et al.  Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. , 1997, Cancer research.

[18]  G. Murphy,et al.  Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.

[19]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[20]  R. Offringa,et al.  Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. , 1996, Journal of immunology.

[21]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[22]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[23]  R. Coleman,et al.  Migration of human dendritic cells after injection in patients with metastatic malignancies. , 1999, Cancer research.

[24]  M. Toungouz,et al.  Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients. , 1999, Cytotherapy.

[25]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.